Overweight, obesity increase risk of cardiotoxicity from anthracyclines

Being overweight or obese was significantly associated with a greater risk of developing cardiotoxicity among breast cancer patients treated with anthracyclines and/or trastuzumab, investigators...
Source: Family Practice News - Category: Primary Care Source Type: news